Mealey's (January 11, 2019, 1:18 PM EST) -- WASHINGTON, D.C. — An appeal of a Delaware federal judge’s determination that a patented pharmaceutical tablet with a core composed of a “macroscopically homogenous composition” for controlling the release of budesonide was not infringed by a proposed generic is before the Federal Circuit, which heard oral arguments in the case on Jan. 10 (Cosmo Technologies Ltd., et al. v. Actavis Laboratories Fl. Inc., et al., Nos. 18-1335, -1336, Fed. Cir.)....